Analysts at Wells Fargo & Company assumed coverage on shares of Humana (NYSE:HUM) in a report issued on Tuesday, The Fly reports. The firm set an “equal weight” rating on the insurance provider’s stock.
A number of other equities analysts have also recently weighed in on the stock. Mizuho upped their price objective on shares of Humana from $462.00 to $480.00 and gave the stock a “buy” rating in a research report on Thursday, April 29th. Zacks Investment Research cut shares of Humana from a “hold” rating to a “sell” rating and set a $447.00 price objective for the company. in a research report on Tuesday, March 30th. Oppenheimer upped their price objective on shares of Humana from $460.00 to $480.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 5th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell upped their price objective on shares of Humana from $496.00 to $510.00 and gave the stock a “buy” rating in a research report on Wednesday, May 5th. Finally, Citigroup upped their price objective on shares of Humana from $496.00 to $510.00 in a research report on Thursday, April 29th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $469.45.
Shares of HUM traded down $1.00 during trading hours on Tuesday, hitting $449.46. The stock had a trading volume of 1,126,584 shares, compared to its average volume of 1,004,180. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.81 and a current ratio of 1.81. The firm has a 50-day moving average price of $437.87 and a 200 day moving average price of $411.85. Humana has a fifty-two week low of $365.06 and a fifty-two week high of $475.44. The firm has a market capitalization of $57.99 billion, a price-to-earnings ratio of 14.41, a PEG ratio of 1.57 and a beta of 0.86.
In related news, insider Timothy S. Huval sold 3,696 shares of the company’s stock in a transaction dated Monday, February 22nd. The shares were sold at an average price of $377.96, for a total value of $1,396,940.16. Following the completion of the sale, the insider now owns 13,068 shares of the company’s stock, valued at $4,939,181.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Timothy Alan Wheatley sold 8,508 shares of the company’s stock in a transaction dated Monday, May 3rd. The shares were sold at an average price of $450.59, for a total transaction of $3,833,619.72. Following the completion of the sale, the insider now directly owns 11,494 shares of the company’s stock, valued at approximately $5,179,081.46. The disclosure for this sale can be found here. Insiders sold 44,897 shares of company stock valued at $17,931,428 over the last quarter. Company insiders own 0.42% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Graves Light Private Wealth Management Inc. purchased a new stake in shares of Humana in the fourth quarter valued at about $27,000. SRS Capital Advisors Inc. boosted its stake in Humana by 322.2% during the fourth quarter. SRS Capital Advisors Inc. now owns 76 shares of the insurance provider’s stock worth $31,000 after buying an additional 58 shares during the period. First Horizon Advisors Inc. purchased a new position in Humana during the fourth quarter worth about $31,000. Jacobi Capital Management LLC boosted its stake in Humana by 271.4% during the first quarter. Jacobi Capital Management LLC now owns 78 shares of the insurance provider’s stock worth $33,000 after buying an additional 57 shares during the period. Finally, Childress Capital Advisors LLC purchased a new position in Humana during the fourth quarter worth about $33,000. 91.90% of the stock is owned by hedge funds and other institutional investors.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Story: What is the Bid-Ask Spread?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.